title: Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration.
abstract: Endocannabinoids (anandamide and 2-AG) are relevant modulators of appetite and energy expenditure through their action on cannabinoid CB(1) receptors. The actions of anandamide on feeding behavior are dependent both, on the anatomical location of CB(1) receptors (central nervous system versus peripheral tissues) and the feeding status. Anandamide uptake into cells, prior to its degradation by specific enzymatic systems, is a necessary step for the regulation of its extracellular levels. The present study explores the route and feeding stimulus dependency of the effects of the anandamide uptake blocker AM404. Peripherally, AM404 reduced feeding in partially satiated animals through a PPARα-independent mechanism, but not in food deprived ones. When AM404 was injected into the cerebral ventricles of food deprived rats, it resulted in hyperphagia that was antagonized by the cannabinoid receptor inverse agonist SR141716A. These results support the multimodal action of endocannabinoid signaling in feeding regulation, which depends on the anatomical site and the feeding status of the animal.
authors: Laboratorio de Medicina Regenerativa, Hospital Regional Universitario Carlos Haya. Fundación IMABIS. Avenida Carlos Haya 82, sótano. Málaga 29010, Spain.
authors: Carmen
authors: C
authors: Reyes-Cabello
authors: Francisco
authors: F
authors: Alen
authors: Raquel
authors: R
authors: Gómez
authors: Antonia
authors: A
authors: Serrano
authors: Patricia
authors: P
authors: Rivera
authors: Laura
authors: L
authors: Orio
authors: Fernando
authors: F
authors: Rodríguez de Fonseca
authors: Francisco Javier
authors: FJ
authors: Pavón
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000378:metabolism* / Q000494:pharmacology*; D004435:Eating / Q000187:drug effects*; D063388:Endocannabinoids; D002149:Energy Intake / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects*; D005508:Food Deprivation / Q000502:physiology*; D007274:Injections, Intraperitoneal; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D009752:Nutritional Status; D010080:Oxazoles / Q000494:pharmacology; D047493:PPAR alpha / Q000235:genetics / Q000502:physiology; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000187:drug effects*; D000077285:Rimonabant; D012527:Satiation / Q000502:physiology; D014443:Tyrosine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D001095:Arachidonic Acids; D063388:Endocannabinoids; C449302:GW 6471; D010080:Oxazoles; D047493:PPAR alpha; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014443:Tyrosine; D000077285:Rimonabant; C078814:anandamide; C107594:N-(4-hydroxyphenyl)arachidonylamide